Panelists discuss how oral iron therapy, although convenient and cost-effective, has significant limitations, including ...

Dr. Eric K. Singhi shares his insights into the advantages of the subcutaneous formulation of Opdivo versus the IV version ...

Among those with advanced gastric cancer, oral Liporaxel showed superior overall survival outcomes versus IV Liporaxel as a ...

Intravenous Opdivo, with $2.48 billion in sales, topped the list of precision oncology products in BMS's growth portfolio.

Panelists discuss how modern FDA-approved intravenous iron formulations, including ferric carboxymaltose, ferumoxytol, and ...

NPPA seeks market-based price data on four IVs for ceiling price fixation: Gireesh Babu, New Delhi Saturday, January 25, 2025, 08:00 Hrs [IST] The National Pharmaceutical Pricing ...

The FDA has approved Avtozma® (tocilizumab-anoh), a biosimilar to Actemra®, in both intravenous and subcutaneous formulations.

The FDA has approved a third biosimilar for tocilizumab, called Avtozma, the second such biosimilar to be available in both intravenous and subcutaneous formulations, according to a press release.

A new study has found small amounts of liquid ketamine administered in a clinical setting can significantly reduce symptoms ...

A phase 2, multicenter, open-label study of AlloStim combined with anti-PD-L1 immunotherapy as 4L therapy in patients with MSS/pMMR metastatic colorectal cancer. This is an ASCO Meeting Abstract from ...